News & Trends - MedTech & Diagnostics
Baxter announces branding for spin-off kidney care business
MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, named Vantive.
The groundwork for Vantive was laid in 2023 when Baxter announced its plans to carve out a standalone Kidney Care entity from its Renal Care and Acute Therapies divisions. The transition to the Vantive branding is slated to coincide with the separation, anticipated in the latter half of 2024, through either a divestiture to a private equity investor or a spinoff into a publicly traded entity.
Focused on delivering critical organ therapies for both acute and chronic kidney care, Vantive pledges to drive its team members towards fervently developing solutions tailored to the needs of clinicians and patients alike. This overarching purpose of ‘Extending Lives, Expanding Possibilities’ underscores the commitment to shaping an enhanced healthcare journey.
The emblem of Vantive showcases a distinctive “V” motif, partitioned into three segments, symbolising the innovative therapies, digital solutions, and advanced services the company is poised to offer. Rendered in a plum hue, the logo strategically combines the ‘stability and trustworthiness’ of Baxter’s primary brand colour, blue, with the ‘energy and boldness’ of red.
Chris Toth, Executive Vice President and Group President of Kidney Care at Baxter, slated to assume the role of Chief Executive Officer at Vantive post-separation, remarked, “With the reveal of our mission and logo, we have reached another critical milestone in our journey to establish Vantive. From our legacy as a pioneer in kidney care to our position as a market leader in chronic and acute therapies, we maintain a unique vantage point to help fulfill the pivotal needs of today’s clinicians and patients.”
Vantive will inherit and uphold Baxter’s storied heritage spanning nearly seven decades, characterised by its contributions and leadership in kidney care and critical organ support therapies. As it ventures forward, the company remains steadfast in its commitment to serving as a trusted ally to healthcare providers and clinicians globally, with a focus on enhancing outcomes for the over one million patients it serves annually across more than 70 nations.
Until the proposed separation culminates, the Kidney Care business will persist under the banner of Baxter, ensuring continuity in operations.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals
Lilly’s drug cuts diabetes risk by 94%, so why is it still not on the PBS?
On World Diabetes Day (14 November), new data reveals that three years of treatment with a GIP/GLP-1 receptor agonist significantly […]
MoreNews & Trends - Biotechnology
Depaz Oration to celebrate an ‘enduring’ legacy in the biotech sector
AusBiotech announced the establishment of the Depaz Oration, an annual keynote event that will debut at the AusBiotech Conference in […]
MoreNews & Trends - Pharmaceuticals
Government calls for public input on genomic-led cancer care
The Australian Government has launched a public consultation on a draft policy framework aimed at enhancing genomics-informed cancer care nationwide. […]
MoreNews & Trends - MedTech & Diagnostics
Can the patient voice reduce low-value care? Australia’s first large-scale hospital initiative seeks answers
In an Australian-first, a not-for-profit private health insurer will ask hospital patients to rate not only their clinical care but […]
More